Comparative Pharmacology
Head-to-head clinical analysis: VITRASE versus XIAFLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VITRASE versus XIAFLEX.
VITRASE vs XIAFLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VITRASE (hyaluronidase) hydrolyzes hyaluronic acid, a component of the extracellular matrix, thereby increasing tissue permeability to fluids and facilitating the absorption and dispersion of injected drugs.
XIAFLEX (collagenase clostridium histolyticum) is a combination of two collagenases (AUX-I and AUX-II) that hydrolyze collagen in the extracellular matrix. It targets type I and type III collagen, leading to enzymatic disruption of collagen-rich structures such as Dupuytren's cords and Peyronie's plaques.
Intravenous administration of 150 units as a bolus injection prior to subcutaneous fluid or medication administration to increase absorption and dispersion.
0.58 mg injected directly into the palpable cord, up to 3 injections per treatment session (one per affected cord) at intervals of 1–2 days apart; repeated every 4 weeks as needed, up to 3 treatment sessions per cord.
None Documented
None Documented
Approximately 24 hours for the enzymatic activity; clinical effect persists beyond half-life due to drug action.
Systemic half-life not applicable due to minimal systemic absorption. Locally, collagenase activity declines within 1-2 days post-injection.
Renal: <10% unchanged; remainder metabolized locally.
Primarily metabolized locally; systemic absorption minimal. No renal or biliary excretion data available; eliminated via local degradation.
Category C
Category C
Enzyme
Enzyme